Methods for treating ocular inflammatory diseases

ABSTRACT

A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent applicationSer. No. 12/399,729, filed on Mar. 6, 2009, the disclosure of which areincorporated by reference herein in their entirety.

BACKGROUND OF THE INVENTION

This invention relates generally to methods for treating ocularinflammatory diseases and, more specifically to methods for treatingblepharitis.

Blepharitis is an ocular disease characterized by inflammation of theeyelid margins. Blepharitis may cause redness of the eyes, itching andirritation of the eyelids in one or both eyes. The pathophysiology ofblepharitis is a complex combination of any number of factors, includingabnormal lid-margin secretions, bacterial organisms, and abnormalitiesof the tear film. Other causative agents of blepharitis can be fungal orviral in origin including, for example, herpes simplex and varicellazoster. Blepharitis can appear along with various dermatologicalconditions including, for example, seborrheic dermatitis, rosacea, andeczema.

Blepharitis occurs in two main forms. The first type, anteriorblepharitis, affects the outside front of the eyelid near the eyelashes.The two most common causes of anterior blepharitis are Staphylococcusbacterial infection and seborrheic dermatitis. The second type,posterior blepharitis, affects the inner eyelid and can be caused byproblems with the meibomian glands. Two skin disorders that commonlycause this form of blepharitis are acne rosacea, which leads to red andinflamed skin, and seborrheic dermatitis. Other conditions may give riseto blepharitis, whether they be infectious or non-infectious, including,but not limited to, bacterial infections or allergies.

Blepharitis has a strong tendency to recur and if left untreated canlead to conjunctivitis and the eyelids can begin to ulcerate in somecircumstances. It is most commonly treated, although not cured, via athorough hygiene regimen that helps remove crusts and some bacterialorganisms. Under duress to prevent or treat ulcerative blepharitis,pharmaceutical interventions have utilized mixtures of anti-inflammatoryagents in conjunction with topical or systemic antibacterial agents.With the ubiquitous usage of antibacterial agents, there is the riskthat organisms will develop drug resistance.

Thus, there exists a need for improved treatments for blepharitis. Thepresent invention satisfies this need and provides related advantages aswell.

SUMMARY OF THE INVENTION

In some aspects, embodiments of the present invention relate to a methodof treating non-infectious, inflammatory blepharitis that includesadministering to the affected eye of a subject an effective amount of anactive ingredient in an ophthalmically acceptable vehicle for asufficient period of time to treat blepharitis. The active ingredientconsists essentially of a glucocorticoid which is provided in anophthalmically acceptable vehicle. The vehicle includes an aqueouspolymer suspension that when mixed with tear fluid provides a sustainedrelease of the active ingredient. The aqueous polymer suspensionincludes a carboxyl-containing polymer having less than about 5% byweight cross-linking agent and has a viscosity in a range from about1,000 to about 30,000 centipoises.

In other aspects, embodiments of the present invention relate to a kitthat includes a composition that includes about 0.1% by weightdexamethasone in an ophthalmically acceptable vehicle. Theophthalmically acceptable vehicle includes an aqueous polymer suspensionthat when mixed with tear fluid provides a sustained release of saidactive ingredient. The aqueous polymer suspension includes acarboxyl-containing polymer having less than about 5% by weightcross-linking agent and has a viscosity in a range from about 1,000 toabout 30,000 centipoises. The kit further includes instructions forusing the composition of (a) for the treatment of blepharitis.

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed, in part, to a method of treatingnon-infectious, inflammatory blepharitis with a glucocorticoid as aprimary active ingredient in the presence a slow release ophthalmiccarrier vehicle. This combination has been found effective inameliorating the clinical signs and symptoms associated withnon-infectious, inflammatory blepharitis. This is in contrast to thestandard pharmaceutical intervention which utilizes an antibiotic incombination with an anti-inflammatory agent. Such formulations known inthe art are exemplified by TOBRADEX® (0.3% tobramycin and dexamethasonealcohol), CORTISPORIN® (neomycin or polymyxin B (10,000 units) withhydrocortisone), Maxitrol (neomycin or polymyxin B (10,000 units) withdexamethasone), BLEPHAMIDE® (10% sulfacetamide and prednisoloneacetate), and VASOCIDIN® (100 mg/mL sulfacetamide & prednisolone sodiumphosphate), all of which use relatively high dosage of antibacterialagent. In addition to undesirable side-effects associated with a numberof the aforementioned antibiotics, increased concern for the developmentof drug-resistant bacterial strains provides the impetus for thedevelopment of new treatment regimens that move away from using suchbroad spectrum antibiotics. The need for reduced dependence on theseantibiotics for treating non-infectious, inflammatory blepharitis is metby the present invention.

Thus, in one embodiment, the invention provides a method of treatingnon-infectious, inflammatory blepharitis that includes administering tothe eye of a subject an effective amount of an active ingredient in anophthalmically acceptable vehicle for a sufficient period of time totreat non-infectious, inflammatory blepharitis. The active ingredientconsists essentially of a glucocorticoid, while the ophthalmicallyacceptable vehicle includes an aqueous polymer suspension that whenmixed with tear fluid of the eye provides a sustained release of theactive ingredient. The aqueous polymer suspension includes acarboxyl-containing polymer having less than about 5% by weightcross-linking agent and has a viscosity in a range from about 1,000 toabout 30,000 centipoises.

As used herein, the term “blepharitis” includes all types of oculardisease characterized by inflammation of the eyelid margins, includingthe broad categories of anterior blepharitis and posterior blepharitis.The term encompasses blepharitis characterized by its pathophysiologicalorigins, including for example, staphylococcal, seborrheic, mixedstaphylococcal and seborrheic, and meibomian gland dysfunction (MGD).Other conditions may give rise to blepharitis, whether they beinfectious or non-infectious, including, but not limited to, bacterialinfections or allergies. Pathophysiological origins for which aglucocorticoid is contraindicated are not encompassed by the term andinclude the less common viral and fungal forms of blepharitis.

As used herein, “administering to the eye of a subject” meansadministering the active ingredient in an ophthalmically acceptablevehicle in the form of an eye drop directly to the eye and/or in theeyelid margins, such administration techniques being familiar to personsskilled in the art.

As used herein, “an effective amount” when used in connection withtreating non-infectious, inflammatory blepharitis is intended to qualifythe amount of a glucocorticoid used in the treatment of treatingnon-infectious, inflammatory blepharitis and/or prophylaxis againstblepharitis. This amount will achieve the goal of preventing, reducing,or eliminating blepharitis. An effective amount includes from about 0.01(mg/mL or μg/mL) to 100 per dose in one embodiment and from about n to mdose in another embodiment. An “effective amount” can include a doseregimen once per day, twice per day, thrice per day, and so on.

As used herein an “ophthalmically acceptable vehicle” is one whichallows delivery of an active ingredient to treat treatingnon-infectious, inflammatory blepharitis without deleterious effects onthe eye. An ophthalmically acceptable vehicle is one that can maintainproper intraocular pressure and provide solutions that are eitherisotonic, mildly hypotonic, or mildly hypertonic. To maintain suchconditions one can include various non-ionic osmolality-adjustingcompounds such as polyhydric alcohols, including for example, glycerol,mannitol, sorbitol, or propylene glycol. Alternatively, osmolalityadjusting compounds can include ionic salts such as sodium or potassiumchloride. An ophthalmically acceptable vehicle can also include buffersto adjust to an acceptable pH, which can range from about 3 to 7.4. Suchbuffer systems include, for example, acetate buffers, citrate buffers,phosphate buffers, borate buffers and mixtures thereof. Specific buffercomponents useful in the present invention include citric acid/sodiumcitrate, boric acid, sodium borate, sodium phosphates, including mono,di- and tri-basic phosphates, such as sodium phosphate monobasicmonohydrate and sodium phosphate dibasic heptahydrate, and mixturesthereof. It should be noted that any other suitable ophthalmicallyacceptable buffer components can be employed to maintain the pH of theophthalmic formulation so that the ophthalmic formulation is providedwith an acceptable pH, and the foregoing buffer components are merelyexemplary of such buffer components.

As used herein, a “sufficient period” for treatment of treatingnon-infectious, inflammatory blepharitis means a sufficient time toprevent, reduce, or eliminate the occurrence of clinical signs andsymptoms associated with treating non-infectious, inflammatoryblepharitis in the eye of a subject. Such an amount of time can beassessed, for example, by evaluating eradication and/or reduction in theclinical signs or symptoms of treating non-infectious, inflammatoryblepharitis and the subject no longer suffers its debilitating effects.For blepharitis of a particular pathophysiological origin, thefrequency, dosage, and length of time can be determined in consultationwith a physician.

As used herein, “clinical signs or symptoms of blepharitis” includeredness and burning sensation of the eyes, itching, gritty irritation ofthe eyelids, flaking of skin around the eyes, redness and swelling ofthe eyelids, crusted scales on the eyelashes, frothy tears, sensitivityto light, loss of eyelashes, misdirected growth of eyelashes, a greasyappearance to the eyelids, sticky secretions near the eyelashes, dry eyesensation, redness in the eyelid margins, tearing, and any combinationthereof.

As used herein “active ingredient” refers to the primary compoundresponsible for reducing, preventing, or eliminating the clinical signsand symptoms of blepharitis. Exemplary active ingredients are theglucocorticoids, as disclosed herein.

As used herein “an ophthalmically acceptable salt” will include thosethat exhibit no deleterious effects on the eye as well as beingcompatible with the active ingredient itself and the components of theophthalmically acceptable vehicle. Salts or zwitterionic forms of theactive ingredient glucocorticoids of the present invention can be wateror oil-soluble or dispersible. The salts can be prepared during thefinal isolation and purification of the glucocorticoid or separately byadjusting the pH of the appropriate glucocorticoid formulation with asuitable acid or base.

In some embodiments, the invention provides a method of treatingtreating non-infectious, inflammatory blepharitis that includesadministering to the affected eye of a subject an effective amount of anactive ingredient in an ophthalmically acceptable vehicle for asufficient period of time to treat treating non-infectious, inflammatoryblepharitis. The active ingredient consists of essentially aglucocorticoid. The ophthalmically acceptable vehicle includes anaqueous polymer suspension that when mixed with tear fluid provides asustained release of the active ingredient. An exemplary aqueous polymersuspension includes a carboxyl-containing polymer having less than about5% by weight cross-linking agent and has a viscosity in a range fromabout 1,000 to about 30,000 centipoises.

In some embodiments, an effective amount of an active ingredient is theamount used in the treatment of treating non-infectious, inflammatoryblepharitis and/or prophylaxis against blepharitis. This amount willachieve the goal of preventing, reducing, or eliminating treatingnon-infectious, inflammatory blepharitis. An effective amount includesfrom about 0.1 μg to 100 μg per dose in one embodiment, and from about 1μg to 10 μg per dose in another embodiment. An effective amount includesall values in between and fractions thereof, for example, about 0.1 μg,0.5 μg, 1 μg, 5 μg, 10 μg, 15 μg, 20 μg, 30 μg, 40 μg, 50 μg, 60 μg, 70μg, 80 μg, 90 μg, up to about 100 μg per dose. An effective amount canadministered in a dosing regimen once per day, twice per day, thrice perday, or any number of times per day and can be determined inconsultation with a physician. An effective amount can be administeredas a solution in eye drop form as about 0.05% to about 0.50% by weightsolution of the active ingredient, including for example, about 0.05%,0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%,0.16%, 0.17%, 0.18%, 0.19%, 0.20%, 0.25%, 0.30%, 0.35%, 0.40%, 0.45%,and about 0.50% and all values in between and fractions thereof.

In some embodiments, an active ingredient consists essentially of aglucocorticoid. Glucocorticoids are potent anti-inflammatory agents andcan often be successfully administered independent of the underlyingcause of inflammation. Without being bound by theory, glucocorticoids'primary anti-inflammatory mechanism are reported to be related tolipocortin-1(annexin-1) synthesis. Lipocortin-1 suppresses phospholipaseA2, thereby blocking eicosanoid production, and inhibits variousleukocyte inflammatory events. In addition, glucocorticoids have beenshown to suppress cyclooxygenases, including COX-1 and COX-2.

Glucocorticoids can initiate an anti-inflammatory effect by binding tothe cytosolic glucocorticoid receptor (GR). After binding GR, thereceptor-ligand complex translocates to the cell nucleus, where it canbind to glucocorticoid response elements (GRE) in the promoter region oftarget genes. The proteins encoded by these upregulated genes have awide range of effects including anti-inflammatory effects mediated, forexample, by lipocortin I as described above. Glucocorticoids can alsoreduce the transcription of pro-inflammatory genes by a mechanism oftransrepression. Thus, inflammation associated with blepharitis can beameliorated by glucocorticoid treatment.

Accordingly, in some embodiments, the active ingredient of thecompositions and methods of the invention consists essentially of aglucocorticoid including, for example, hydrocortisone, cortisoneacetate, prednisone, prednisolone, methylprednisolone, dexamethasone,betamethasone, triamcinolone, and beclomethasone, fluorometholone. Otherglucocorticoids useful in the method for treating blepharitis include,for example, 21-acetoxypregnenolone, alclometasone, algestone,amcinonide, budesonide, chloroprednisone, clobetasol, clobetasone,clocortolone, cloprednol, corticosterone, cortisone, cortivazol,deflazacort, desonide, desoximetasone, diflorasone, diflucortolone,difluprednate, enoxolone, fluazacort, flucloronide, flumethasone,flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl,fluocortolone, fluperolone acetate, fluprednidene acetate,fluprednisolone, flurandrenolide, fluticasone propionate, formocortal,halcinonide, halobetasol propionate, halometasone, halopredone acetate,hydrocortarnate, loteprednol etabonate, mazipredone, medrysone,meprednisone, mometasone furoate, paramethasone, prednicarbate,prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate,prednival, prednylidene, rimexolone, tixocortol, triamcinoloneacetonide, triamcinolone benetonide, triamcinolone hexacetonide, theiropthalmically acceptable salts, combinations thereof, and mixturesthereof. In one embodiment, the glucocorticoid includes dexamethasone,prednisone, prednisolone, methylprednisolone, medrysone, triamcinolone,loteprednol etabonate, opthalmically acceptable salts thereof,combinations thereof, and mixtures thereof.

The effects of treating treating non-infectious, inflammatoryblepharitis with dexamethasone, in particular, with the aid of theslow-release ophthalmically acceptable carrier, are shown in the Examplebelow, although any of the aforementioned glucocorticoids are useful inthe treatment of treating non-infectious, inflammatory blepharitis. Inaccordance with various embodiments of the invention, dexamethasoneincludes, for example, dexamethasone sodium phosphate, dexamethasone(alcohol), dexamethasone acetate, dexamethasone dimethylbutyrate,dexamethasone trimethylacetate, dexamethasone dipropionate,dexamethasone acefurate, and mixtures thereof.

In some embodiments the glucocorticoid is present in a range from about0.05% and to about 0.5% by weight, while in other embodiments theglucocorticoid is present in a range from about 0.08% to about 0.12% byweight. The amount of glucocorticoid based on weight percent can be anyvalue between these values, including for example, 0.05%, 0.060%, 0.07%,0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%,0.18%, 0.19%, 0.20%, 0.25%, 0.30%, 0.35%, 0.40%, 0.45%, and about 0.50%by weight and all values in between and fractions thereof. A standardsolution of dexamethasone, in particular, for ophthalmic use is about0.10% by weight.

In some embodiments, the ophthalmically acceptable vehicle usesinsoluble polymers to provide a gel or liquid drops which release thedrug over time. The polymer is about 0.1 to about 6.5% in someembodiments, and, in other embodiments about 1.0 to about 1.3% by weightbased on the total weight of the suspension of a cross-linkedcarboxy-containing polymer. Suitable carboxy-containing polymers aredescribed, for example, in U.S. Pat. No. 5,192,535 to Davis et al. whichis hereby incorporated by reference. These polymer carriers includelightly crosslinked carboxy-containing polymers (such as polycarbophil,or Noveon AA-1) dextran, cellulose derivatives, polyethylene glycol 400and other polymeric demulcents such as polyvinylpyrolidone,polysaccaride gels and GELRITE®. A carboxy-containing polymer systemknown by the tradename DuraSite®, containing polycarbophil, is asustained release topical ophthalmic delivery system that releases thedrug at a controlled rate, can also be used.

In accordance with some embodiments, a sustained release topicalophthalmically acceptable carrier includes an aqueous suspension at a pHof from about 3 to about 6.5 and an osmotic pressure of from about 10 toabout 400 mOsM containing from about 0.1% to about 6.5% by weight, basedon the total weight of the suspension, of a carboxyl-containing polymerprepared by polymerizing one or more carboxyl-containingmonoethylenically unsaturated monomers and less than about 5% by weightof a cross-linking agent, such weight percentages of monomers beingbased on the total weight of monomers polymerized. The suspension has aninitial viscosity of from about 1,000 to about 30,000 centipoises and isadministrable to the eye in drop form at that initial viscosity. Thepolymer has average particle size of not more than about 50 μm,preferably not more than about 30 μm, in equivalent spherical diameter.It is lightly cross-linked to a degree such that although the suspensionis administrable in drop form, upon contact of the lower pH suspensionwith the higher pH tear fluid of the eye, the suspension is rapidlygellable to a substantially greater viscosity than the viscosity of thesuspension as originally administered in drop form. Accordingly, theresulting more viscous gel can remain in the eye for a prolonged periodof time so as to release a medicament contained therein in sustainedfashion.

The polymer is, in one embodiment, prepared from at least about 50% byweight, and in other embodiments from at least about 90% by weight, ofone or more carboxyl-containing monoethylenically unsaturated monomers.The polymer can be prepared by suspension or emulsion polymerizingacrylic acid and a non-polyalkenyl polyether difunctional cross-linkingagent to a particle size of not more than about 50 μm in one embodiment,and not more than about 30 μm, in equivalent spherical diameter, inother embodiments. In one embodiment, the cross-linking agent is divinylglycol. In other embodiments, one can replace up to about 40% by weightof the carboxyl-containing monoethylenically unsaturated monomers by oneor more non-carboxyl-containing monoethylenically unsaturated monomerscontaining only physiologically and ophthamologically innocuoussubstituents.

The osmotic pressure is, in some embodiments, achieved by using aphysiologically and ophthalmologically acceptable salt in an amount offrom about 0.01% to about 1% by weight, based on the total weight of thesuspensions. Exemplary salts include potassium and sodium chlorides.

In some embodiments, in a method of preparing sustained release topicalophthalmically acceptable vehicles, the foregoing suspensions areprepared and packaged at the desired viscosity of from 1,000 to about30,000 centipoises for administration to the eye in drop form. In oneexemplary delivery method, the foregoing suspensions, containing theactive ingredient, are administered to the eye at the initial viscosityin drop form to cause the administered suspension, upon contact with thehigher pH tear fluid of the eye, to rapidly gel in situ to asubstantially greater viscosity than the viscosity of the suspension asoriginally administered in drop form. The more viscous gel remains inthe eye for a prolonged period of time so as to release the activeingredient, entrapped in the more viscous gel formed in the eye, insustained fashion.

In contrast to other systems, the present invention provides anophthalmically acceptable vehicle that not only has the benefits ofadministration in drop form, but also does not suffer from breakdownlimitations due to administration at a viscosity suitable for drops.Through administration at a viscosity such that the suspension can bereliably administered in drop form, but which actually increases whenthe suspension is so administered, controlled release of the activeingredient is significantly enhanced.

As mentioned above, viscosities substantially over 30,000 cps are notuseful for drop formulations. When the viscosities are substantiallylower than 1,000 cps, the ability to gel upon contact with tears can beimpeded. The increased gelation occurs with a pH change when thesuspension at a pH of from about 3 to about 6.5 and an osmotic pressureof from about 10 to about 400 mOsM contacts the tear fluid. As will beappreciated, tear fluid is at a higher pH of about 7.2 to about 7.4.With the pH increase, the carboxylic acid (COOH) functional groupreplaces the ionizable hydrogen cation with sodium (to COONa), and thesodium form disassociates, causing the polymer to expand.

This is where relationships of cross-linking and particle size becomequite significant. Because the particles are present in a suspension,the degree of cross-linking is necessarily at a level to avoidsubstantial dissolution of the polymer. On the other hand, since rapidgelation is achieved at the time of the pH change, the degree ofcross-linking is necessarily not so great that gelation is precluded.Moreover, if the polymer particle size is too large, induced swellingtends to take up voids in the volume between large particles that are incontact with one another, rather than causing gelation.

If the polymer were in a dissolved state, as it would be if there wereinsufficient cross-linking due to, e.g., an insufficiently low ratio ofcross-linker to monomer, particle size would be basically irrelevant. Ina therapeutic, topical suspension, particle size can be relevant topatient comfort. However, it has been found that in the system of thepresent invention, the small particle size and light cross-linkingsynergistically yield rapid gelation to provide a substantiallyincreased viscosity when the pH changes. In fact, above the 50 μm sizethis advantage of substantially increased viscosity is not realized, butat the 50 μm size, there is also reasonably good eye comfort.

In some embodiments, the particles are not only subject to the uppersize limits described above, but also to a narrow particle sizedistribution. Such use of a monodispersion of particles, which aids ingood particle packing, yields a maximum increased viscosity upon contactof the suspension with the tears and increases eye residence time. Atleast about 80% in some embodiments, at least about 90% in otherembodiments, and at least about 95% in still other embodiments, of theparticles should be within a 10 μm or less band of major particle sizedistribution, and overall (i.e., considering particles both within andoutside such band) there should be no more than about 20%, in someembodiments, and no more than about 10%, in other embodiments, and nomore than about 5%, in still other embodiments, fines (i.e., particlesof a size below 1 μm). In some embodiments, the average particle size islowered from the upper limit of 50 μm, such as 30 μm, and to lower sizessuch as 6 μm, that the band of major particle size distribution be alsonarrowed, for example to 5 μm. In some embodiments, sizes for particleswithin the band of major particle distribution are less than about 30μm, less than about 20 μm in other embodiments, and from about 1 μm toabout 5 μm in still other embodiments.

The lightly cross-linked polymers of acrylic acid or related alpha,beta-unsaturated carboxylic acids used in ophthalmically acceptablevehicle are well known in the art. In one embodiment such polymers areprepared from at least about 90%, or about 95%, or about 99.9% byweight, based on the total weight of monomers present, of one or morecarboxyl-containing monoethylenically unsaturated monomers. Acrylic acidis a common carboxyl-containing monoethylenically unsaturated monomer,but other unsaturated, polymerizable carboxyl-containing monomers, suchas methacrylic acid, ethacrylic acid, β-methylacrylic acid (crotonicacid), cis-α-methylcrotonic acid (angelic acid), trans-α-methylcrotonicacid (tiglic acid), α-butylcrotonic acid, α-phenylacrylic acid,α-benzylacrylic acid, α-cyclohexylacrylic acid, β-phenylacrylic acid(cinnamic acid), coumaric acid (o-hydroxycinnamic acid), umbellic acid(p-hydroxycoumaric acid), and the like can be used in addition to orinstead of acrylic acid.

Such polymers are cross-linked by using a small percentage, i.e., lessthan about 5%, such as from about 0.5% or from about 0.1% to about 5%,and in other emboidments from about 0.2% to about 1%, based on the totalweight of monomers present, of a polyfunctional cross-linking agent.Included among such cross-linking agents are non-polyalkenyl polyetherdifunctional cross-linking monomers such as divinyl glycol;2,3-dihydroxyhexa-1,5-diene; 2,5-dimethyl-1,5-hexadiene; divinylbenzene;N,N-diallylacrylamide; N,N-di allylmethacrylamide and the like. Alsoincluded are polyalkenyl polyether cross-linking agents containing twoor more alkenyl ether groupings per molecule, preferably alkenyl ethergroupings containing terminal H₂ C═C< groups, prepared by etherifying apolyhydric alcohol containing at least four carbon atoms and at leastthree hydroxyl groups with an alkenyl halide such as allyl bromide orthe like, e.g., polyallyl sucrose, polyallyl pentaerythritol, or thelike; see, e.g., Brown U.S. Pat. No. 2,798,053. Diolefinicnon-hydrophilic macromeric cross-linking agents having molecular weightsof from about 400 to about 8,000, such as insoluble di- andpolyacrylates and methacrylates of diols and polyols,diisocyanate-hydroxyalxyl acrylate or methacrylate reaction products,and reaction products of isocyanate terminated prepolymers derived frompolyester diols, polyether diols or polysiloxane diols withhydroxyalkylmethacrylates, and the like, can also be used as thecross-linking agents; see, e.g., Mueller et al. U.S. Pat. Nos. 4,192,827and 4,136,250.

The lightly cross-linked polymers can be made from a carboxyl-containingmonomer or monomers as the sole monoethylenically unsaturated monomerpresent, together with a cross-linking agent or agents. They can also bepolymers in which up to about 40%, and in some embodiments, from about0% to about 20% by weight, of the carboxyl-containing monoethylenicallyunsaturated monomer or monomers has been replaced by one or morenon-carboxyl-containing monoethylenically unsaturated monomerscontaining only physiologically and ophthalmologically innocuoussubstituents, including acrylic and methacrylic acid esters such asmethyl methacrylate, ethyl acrylate, butyl acrylate,2-ethylhexylacrylate, octyl methacrylate, 2-hydroxyethyl-methacrylate,3-hydroxypropylacrylate, and the like, vinyl acetate,N-vinylpyrrolidone, and the like; see Mueller et al. U.S. Pat. No.4,548,990 for a more extensive listing of such additionalmonoethylenically unsaturated monomers. Particularly preferred polymersare lightly cross-linked acrylic acid polymers wherein the cross-linkingmonomer is 2,3-dihydroxyhexa-1,5-diene or 2,3-dimethylhexa-1,5-diene.

Exemplary commercially available lightly cross-linked polymers useful inthe invention include, for example, polycarbophil (available, forexample, from Lubizol,), a polyacrylic acid cross-linked with divinylglycol. Without being bound by theory, this polymer benefits from itsmucoadhesive properties which aid in increasing the residence time ofthe active ingredient in the eye. Other mucoadhesive polymers can beused in conjunction with, or in lieu of the lightly cross-linkedpolymers disclosed herein, for example, Carbopol 934P, Carbopol 980 orhyaluronic acid. The latter has been demonstrated to be an effectivemucoadhesive polymer in ocular formulations (Saettone et al. Int. J.Pharm. 51: 203-212, (1989)).

The lightly cross-linked polymers used in practicing this invention canbe prepared by suspension or emulsion polymerizing the monomers, usingconventional free radical polymerization catalysts, to a dry particlesize of not more than about 50 μm in equivalent spherical diameter;e.g., to provide dry polymer particles ranging in size from about 1 toabout 30 μm, and in other embodiments from about 3 to about 20 μm, inequivalent spherical diameter. In general, such polymers will range inmolecular weight estimated to be about 250,000 to about 4,000,000,000and in some embodiments, about 500,000 to about 2,000,000,000.

Aqueous suspensions containing polymer particles prepared by suspensionor emulsion polymerization whose average dry particle size isappreciably larger than about 50 μm in equivalent spherical diameter areless comfortable when administered to the eye than suspensions otherwiseidentical in composition containing polymer particles whose equivalentspherical diameters are, on the average, below about 50 μm. Moreover,above the average 50 μm size, the advantage of substantially increasedviscosity after administration is not realized. It has also beendiscovered that lightly cross-linked polymers of acrylic acid or thelike prepared to a dry particle size appreciably larger than about 50 μmin equivalent spherical diameter and then reduced in size, e.g., bymechanically milling or grinding, to a dry particle size of not morethan about 50 μm in equivalent spherical diameter do not work as well aspolymers made from aqueous suspensions. While not being bound by anytheory or mechanism advanced to explain the functioning of thisinvention, one possible explanation for the difference of suchmechanically milled or ground polymer particles as the sole particulatepolymer present is that grinding disrupts the spatial geometry orconfiguration of the larger than 50 μmm lightly cross-linked polymerparticles, perhaps by removing uncross-linked branches from polymerchains, by producing particles having sharp edges or protrusions, or byproducing ordinarily too broad a range of particle sizes to affordsatisfactory delivery system performance. A broad distribution ofparticle sizes will impair the viscosity-gelation relationship. In anyevent, such mechanically reduced particles are less easily hydratable inaqueous suspension than particles prepared to the appropriate size bysuspension or emulsion polymerization, and also are less able to gel inthe eye under the influence of tear fluid to a sufficient extent and areless comfortable once gelled than gels produced in the eye using theaqueous suspensions of this invention. However, up to about, 40% byweight, e.g., from about 0% to over 20% by weight, based on the totalweight of lightly cross-linked particles present, of such milled orground polymer particles can be admixed with solution or emulsionpolymerized polymer particles having dry particle diameters of not morethan about 50 μm when practicing this invention. Such mixtures will alsoprovide satisfactory viscosity levels in the ophthalmically acceptablevehicle and in the in situ gels formed in the eye coupled with ease andcomfort of administration and satisfactory sustained release of theactive ingredient to the eye, particularly when such milled or groundpolymer particles, in dry form, average from about 0.01 to about 30 μm,and in other embodiments, from about 1 to about 5 μm, in equivalentspherical diameter.

In some embodiments, the particles have a narrow particle sizedistribution within a 10 μm band of major particle size distributionwhich contains at least 80%, in other embodiments at least 90%, and instill other embodiments at least 95% of the particles. Also, there is nomore than 20%, and in other embodiments no more than 10%, and in stillother embodiments no more than 5% particles of a size below 1 μm. Thepresence of large amounts of such fines has been found to inhibit thedesired gelation upon eye contact. Apart from that, the use of amonodispersion of particles will give maximum viscosity and an increasedeye residence time of the active ingredient in the ophthalmicallyacceptable vehicle for a given particle size. Monodisperse particleshaving a particle size of 30 μm and below are present in someembodiments. Good particle packing is aided by a narrow particle sizedistribution.

The aqueous suspensions of this invention can contain amounts of lightlycross-linked polymer particles ranging from about 0.1% to about 6.5% byweight, and in other embodiments from about 0.5% to about 4.5% byweight, based on the total weight of the aqueous suspension. They can beprepared using pure, sterile water, preferably deionized or distilled,having no physiologically or ophthalmologically harmful constituents,and will be adjusted to a pH of from about 3.0 to about 6.5, and inother embodiments from about 4.0 to about 6.0, using any physiologicallyand ophthalmologically acceptable pH adjusting acids, bases or buffers,e.g., acids such as acetic, boric, citric, lactic, phosphoric,hydrochloric, or the like, bases such as sodium hydroxide, sodiumphosphate, sodium borate, sodium citrate, sodium acetate, sodiumlactate, THAM (trishydroxymethylaminomethane), or the like and salts andbuffers such as citrate/dextrose, sodium bicarbonate, ammonium chlorideand mixtures of the aforementioned acids and bases.

When formulating the aqueous suspensions of this invention, theirosmotic pressure (π) will be adjusted to from about 10 milliosmolar(mOsM) to about 400 mOsM, and preferably from about 100 to about 250mOsM, using appropriate amounts of physiologically andophthalmologically acceptable salts. Sodium chloride can be used toapproximate physiologic fluid, and amounts of sodium chloride rangingfrom about 0.01% to about 1% by weight, and in other embodiments fromabout 0.05% to about 0.45% by weight, based on the total weight of theaqueous suspension, will give osmolalities within the above-statedranges. Equivalent amounts of one or more salts made up of cations suchas potassium, ammonium and the like and anions such as chloride,citrate, ascorbate, borate, phosphate, bicarbonate, sulfate,thiosulfate, bisulfite and the like, e.g., potassium chloride, sodiumthiosulfate, sodium bisulfite, ammonium sulfate, and the like can alsobe used in addition to or instead of sodium chloride to achieveosmolalities within the above-stated ranges.

The amounts of lightly cross-linked polymer particles, the pH, and theosmotic pressure chosen from within the above-stated ranges can becorrelated with each other and with the degree of cross-linking to giveaqueous suspensions having viscosities ranging from about 1,000 to about30,000 centipoise, and in other embodiments from about 5,000 to about20,000 centipoise, as measured at room temperature (about 25° C.) usinga Brookfield Digital LVT Viscometer equipped with a number 25 spindleand a 13R small sample adapter at 12 rpm. The correlations of thoseparameters are also such that the suspensions will gel on contact withtear fluid to give gels having viscosities estimated to range from about75,000 to about 500,000 centipoise, e.g., from about 200,000 to about300,000 centipoise, measured as above, depending on pH as observed, forexample, from pH-viscosity curves. This effect is noted by observing amore viscous drop on the eye as a set cast. The cast, after setting, canbe easily removed.

The viscous gels that result from fluid eyedrops delivered by means ofthe aqueous suspensions of this invention have residence times in theeye ranging from about 2 to about 12 hours, e.g., from about 3 to about6 hours. The active ingredients contained in these ophthalmicallyacceptable vehicles can be released from the gels at rates that dependon such factors as the active ingredient itself and its physical form,the extent of drug loading and the pH of the system, as well as on anydrug delivery adjuvants, such as ion exchange resins compatible with theocular surface, which can also be present. For fluorometholone, forexample, release rates in the rabbit eye in excess of four hours, asmeasured by fluorometholone contained in the aqueous humor, have beenobserved.

The active ingredient-ophthalmically acceptable vehicle can beformulated in any of several ways. For example the active ingredient,the lightly cross-linked polymer particles, and the osmolality-adjustingsalt can be preblended in dry form, added to all or part of the water,and stirred vigorously until apparent polymer dispersion is complete, asevidenced by the absence of visible polymer aggregates. Sufficient pHadjusting agent is then added incrementally to reach the desired pH, andmore water to reach 100 percent formula weight can be added at thistime, if necessary. Another convenient method involves adding the drugto about 95 percent of the final water volume and stirring for asufficient time to saturate the solution. Solution saturation can bedetermined in known manner, e.g., using a spectrophotometer. The lightlycross-linked polymer particles and the osmolality-adjusting salt arefirst blended in dry form and then added to the drug-saturatedsuspension and stirred until apparent polymer hydration is complete.Following the incremental addition of sufficient pH adjusting agent toreach the desired pH, the remainder of the water is added, withstirring, to bring the suspension to 100 percent formula weight.

These aqueous suspensions can be packaged in preservative-free,single-dose non-reclosable containers. This permits a single dose of theactive ingredient to be delivered to the eye one drop at a time, withthe container then being discarded after use. Such containers eliminatethe potential for preservative-related irritation and sensitization ofthe corneal epithelium, as has been observed to occur particularly fromophthalmic medicaments containing mercurial preservatives. Multiple-dosecontainers can also be used, if desired, particularly since therelatively low viscosities of the aqueous suspensions of this inventionpermit constant, accurate dosages to be administered dropwise to the eyeas many times each day as necessary.

In those vehicles where preservatives are to be included, suitablepreservatives include, for example, chlorobutanol, Polyquat,benzalkonium chloride, cetyl bromide, benzethonium chloride, cetylpyridinium chloride, benzyl bromide, EDTA, phenylmercury nitrate,phenylmercury acetate, thimerosal, merthiolate, acetate andphenylmercury borate, chlorhexidine, polymyxin B sulphate, methyl andpropyl parabens, phenylethyl alcohol, quaternary ammonium chloride,sodium benzoate, sodium proprionate, sorbic acid, and sodium perborate,and combinations thereof. In particular embodiments, the preservativeincludes benzalkonium chloride.

In some embodiments, the preservative is present in a range from about0.001 to about 0.005% by weight. The preservative can be present atabout 0.001, 0.002, 0.003, 0.004, 0.005 and any amount in between theseamounts. In particular, the present invention has the benefit ofsubstantial reduction in the use of a bactericidal component. Thus, insome embodiments, the present invention provides an ophthalmicallyacceptable vehicle having less than about 0.02% of a preservative withbactericidal activity in one embodiment, and less than about 0.01%,0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, or0.001%, in other embodiments.

In some embodiments, the ophthalmically acceptable vehicle includes awetting agent. Such agents can be useful in distributing the activeingredient in an otherwise predominantly aqueous environment. Suchwetting agents include, for example, Poloxamer 407, a triblock copolymerconsisting of a central hydrophobic block of polypropylene glycolflanked by two hydrophilic blocks of polyethylene glycol. Other wettingagents that can be used include carboxymethylcellulose, hydroxypropylmethylcellulose, glycerin, mannitol, polyvinyl alcohol,hydroxyethylcellulose, and combinations thereof.

In some embodiments, the ophthalmically acceptable vehicle can include athickening agent, a second polymer or viscosfier that modulates theviscosity of the vehicle. These include, without limitation, polyvinylalcohol, polyacrylic acid, polyethylene oxide, chitosan, chitosan salts,cellulosic polymers, such as hydroxypropylmethyl cellulose (HPMC), andhydroxymethyl cellulose (HMC), polysaccharide gels/gums such as gumarabic, locust bean gum, gellan gum and xanthan gum.

The second polymer can be any polymer that can enhance the viscosity andmucoadhesive properties of the vehicle where the combination is greaterthan each individual polymer alone and is also ophthalmicallyacceptable. Numerous examples of ophthalmically acceptable polymers aredisclosed in Wagh et al. Asian J. Pharmaceutics (2008), which isincorporated by reference herein in its entirety. Exemplary secondpolymers include, without limitation, hydroxyproplymethyl cellulose(HPMC), hydroxypropyl cellulose (HPC), methyl cellulose (MC),hydroxyethyl cellulose (HEC), polyacrylic acid (PAA), polyvinyl alcohol,carbomers, sodium hyaluronate, chitosan, cyclodextrins, polygalacturonicacid, polyitaconic acid, xyloglucan, xanthan gum, gellan gum,polyorthoesters, celluloseacetophthalate, poloxamer 407,polyethyleneimine, and polyethylene oxide. In some embodiments, thesecond polymer can be a neutral polymer, a cationic polymer, or a secondanionic polymer.

In particular embodiments, the second polymer can be a cationic polymer.Cationic polymers include any ophthalmically acceptable polyaminepolymer capable of modulating the Theological and/or mucoadhesiveproperties of the vehicle. Such polyamines include, for example,poly-L-lysine (PLL), chitosan, a naturally occurring polysaccharidecontaining D-glucosamine, polyethyleneimine (PEI), and polyquaterniumcompounds that include but not limited to Polyquaternium 1,Polyquaternium 7, and Polyquarternium 10. Without being bound by theory,a cationic polymer can impact the vehicle characteristics in at leasttwo different ways. Firstly, the cationic polymer can enhanceelectrostatic interactions between the carrier and the negativelycharged mucins of the corneal epithelium. Such an interaction can conferbeneficial mucoadhesive properties to the vehicle. Secondly, theviscosity of the aqueous suspension of the carboxy-containing polymer isincreased by the addition of a cationic polymer, even prior toadministration to the eye. Again, without being bound by theory, thecationic polyamine polymer can assist in particle aggregation throughhydrogen bonding and/or by electrostatic interactions to effectivelygenerate larger molecular weight constructs which increase the aqueoussuspension's viscosity. In order to realize the benefits of the addedcationic polymer, it should present in an amount that allows theparticles of the carboxy-containing polymer to remain suspended, sincethese advantages are lost upon removal of the carboxy-containingparticles from a suspended state. The increased viscosity of the dualcationic polymer/carboxy-containing polymer system can also help counterthe effects of the clearance mechanisms in the eye.

In some embodiments, the cationic polymer is chitosan. Chitosan isobtained by deacetylation of chitin and possesses mucoadhesiveproperties due to electrostatic interaction between positively chargedchitosan ammonium groups and negatively charged mucosal surfaces.Chitosan is a linear polysaccharide composed of randomly distributed.beta.-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine. Chitosanis available with varying degrees of deacetylation (% DA) and isgenerally produced in a range from between about 60 to about 100%deacetylation. The amino group in chitosan has a pKa value of about 6.5,thus, chitosan is positively charged and soluble in acidic to neutralsolution with a charge density dependent on pH and the % DA-value.Chitosan can enhance the transport of polar drugs across epithelialsurfaces, and is considered biocompatible and biodegradable.

In some embodiments, chitosan used in the vehicle has a molecular weightin a range from between about 50 kDa to about 100 kDa, including anyweights in between, while in other embodiments, chitosan used in thevehicle has a molecular weight in a range from between about 1,000 toabout 3,000 kDa, and any weights in between. As shown in U.S. Pat. No.8,501,800 and Example II below, the range between about 1,000 kDa andabout 3,000 kDa appears to have a larger impact on viscosity of thevehicle, even at very small concentrations of the cationic polymer. Inorder to achieve comparable viscosities with chitosan alone, solutionsof chitosan several orders of magnitude more concentrated have beenused, for example, from between about 2% to about 4%.

In the ophthalmically acceptable vehicle of the present invention,chitosan or other second polymer is present in an amount ranging frombetween about 0.01% to about 0.5% when using a cationic polymer having amolecular weight ranging from about 50 kDa to about 100 kDa. The amountof cationic polymer or chitosan can be any amount in between, includingabout 0.01%, 0.025%, 0.05%. 0.075%, 0.10%, 0.15%, 0.20%, 0.25%, 0.30%,0.35%, 0.40%, 0.45%, and 0.50% and any amount in between these values.When using higher molecular weight cationic polymers, such as betweenabout 1,000 to about 3,000 kDa, the amount of cationic polymer necessaryto achieve favorable viscosities can be substantially reduced. Forexample, the amount of 1,000 kDa to about 3,000 kDa chitosan can be in arange between about 0.01% and 0.5%, or any amount in between including,for example, 0.01%, 0.015%, 0.020%, 0.025%, 0.030%, 0.035%, 0.040%,0.045%, 0.05%, 0.1%, 0.15%, 0.20%, 0.25%, 0.30%, 0.35%, 0.40%, 0.45%,and 0.50%.

In some embodiments, the viscosity is in a range from about 1,000 toabout 30,000 centipoise, and in other embodiments from about 5,000 toabout 20,000 centipoise. In yet other embodiments, the viscosity is in arange from about 10,000 to about 15,000 centipoise. The viscosity rangecan also be between about 1,000 and 5,000 centipoise, including 1,000,1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4500, and 5,000 and all valuesin between. The viscosity range can also be between about 5,000 to about10,000 centipoise, including 5,000, 5,500, 6,000, 6,500, 7,000, 7,500,8,000, 8,500, 9,000, 9,500, and 10,000 and all values in between. Theviscosity range can also be between about 10,000 to about 15,000centipoise, including 10,000, 10,500, 11,000, 11,500, 12,000, 12,500,13,000, 13,500, 14,000, 14,500, and 15,000 and all values in between.The viscosity range can also be between about 15,000 to about 20,000centipoise, including 15,000, 15,500, 16,000, 16,500, 17,000, 17,500,18,000, 18,500, 19,000, 19,500, and 20,000 and all values in between.The viscosity range can also be between about 20,000 to about 30,000centipoise, including 20,000, 21,000, 22,000, 23,000, 24,000, 25,000,26,000, 27,000, 28,000, 29,000, and 30,000 and all values in between. Inparticular embodiments the viscosity is in a range from between about1000 to about 2000, including, for example, about 1,000, 1,050, 1,100,1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600,1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, and 2,000 and allvalues in between.

In some embodiments, the invention is directed to a kit which includes:(a) a composition comprising about 0.1% by weight dexamethasone in anophthalmically acceptable capable of slow release as detailed herein and(b) instructions for using the composition of (a) for the treatment ofblepharitis.

In some embodiments, the kit further includes a means for administeringthe composition. In some embodiments, the means for administering caninclude a bottle, dropper, cup, specialized eye-wash apparatus, wettedtowel or sponge. In some embodiments, the kit includes a cleaningapparatus (e.g., a towel, pad, cloth, brush, sponge, etc.) and/or acleaning solution (e.g., purified water, a detergent solution, a boricacid solution, etc.). In some embodiments of the present invention, theocular area is cleaned prior to administration of the composition of thepresent invention.

The composition can be individually packaged for a single doseadministration; e.g., in a bottle, jar, ampoule, tube, syringe,envelope, container, or vial. When the composition is individuallypackaged, in some embodiments, the composition does not include apreservative. Alternatively, the composition can be contained in apackage that is capable of holding multiple units; e.g., in resealableglass or plastic packages. In some kits, the components of thecomposition are mixed together immediately preceding their usage. Forexample, in some embodiments one or more dry components of thecomposition of the kit are packaged in a separate container; e.g., aplastic bottle, and then mixed with one or more of the liquid componentsof the composition immediately prior to use. Optionally, the kit of thepresent invention can include a dropper or other device for transferringor administering the composition to a subject.

The kit can further include instructions for using the composition ofthe present invention. For example, such instructions can be in a formprescribed by a governmental agency regulating the manufacture, use orsale of pharmaceuticals or biological products, which reflects approvalby the agency of the manufacture, use or sale for human application. Insome embodiments, the kit further includes information on the use of thecomposition or a pre-recorded media device which, e.g., providesinformation on the use of the method of the present invention.

The kit can also include a container for storing the components of thekit. The container can be, for example, a bag, box, envelope or anyother container suitable for use in the present invention. In someembodiments, the container is large enough to accommodate each componentof the present invention. However, in some cases, it can be desirable tohave a smaller container which is large enough to carry only some of thecomponents.

It is understood that modifications which do not substantially affectthe activity of the various embodiments of this invention are alsoincluded within the definition of the invention provided herein.Accordingly, the following examples are intended to illustrate but notlimit the present invention.

EXAMPLE I Dexamethasone to Treat Blepharitis

This Example shows a composition with 0.1% Dexamethasone that is usefulin a method for treating blepharitis.

Table 1 below provides an exemplary formulation of the glucocorticoiddexamethasone as a 0.1% in an exemplary ophthalmically acceptablevehicle of the invention.

TABLE 1 CONCENTRATION INGREDIENT (% W/W) Dexamethasone, USP 0.10Mannitol, USP 1.0 Citric Acid 0.20 Anhydrous, USP Sodium Citrate 0.14Dihydrate, USP Poloxamer 407, NF 0.20 Benzalkonium 0.003 Chloride, NFPolycarbophil, USP 0.90 Sodium Chloride, USP 0.45 Edetate Disodium 0.10Dihydrate, USP Sodium Hydroxide, 2N Adjust to pH 6.3 Water ForInjection, USP q.s. to 100%

In this example, a clinical study was to evaluate the clinical andanti-microbial efficacy and safety of three compositions, 1) 1.0%Azithromycin and 0.1% Dexamethasone in the DURASITE vehicle (Az+Dex) 2)1.0% Azithromycin alone in the DURASITE vehicle (Az) and 3)dexamethasone alone in the DURASITE vehicle (Dex) (Table 1) in thetreatment of subjects with blepharoconjunctivitis.

In this Example, 417 subjects were enrolled, and 386 completed thestudy. 417 subjects received at least one dose of study drug, 417subjects had at least one post-dose clinical assessment and wereincluded in the Intent-to-Treat (ITT) population, 301 subjects in theITT population had positive bacterial cultures at baseline and wereincluded in the modified ITT (mITT) population, and 382 subjects in theITT population had no significant protocol violations and were includedin the Per Protocol (PP) Population.

For clinical diagnosis of blepharoconjunctivitis, subjects had a minimumscore of ‘1’ for:

-   -   one of the lid signs (lid margin redness or lid swelling)    -   one of the conjunctival signs (bulbar conjunctival redness,        palpebral conjunctival redness, or ocular discharge); and,    -   one of the symptoms (lid irritation, itchy eyelids, gritty eyes,        or painful/sore eyes) in at least one eye. Subjects must also        have had a minimum total score of 5 in this eye to be eligible        for entry.

Subjects were randomly assigned to three groups with a 1:1:1 ratio:Az+Dex, Az, and Dex. Subjects were dosed with Az+Dex, Az, or Dex BID atapproximately 12-hour intervals for 14 days in both eyes. Subjects wereinstructed to place one drop on their eyelids and one drop into theireyes. This was a multi-center, randomized, double-masked, 3-arm,parallel-group, comparative clinical trial, with one interim analysis.

After subjects met all entry criteria and signed informed consent, theyunderwent evaluations for visual acuity, biomicroscopy, ophthalmoscopy,and IOP. Signs and symptoms were evaluated, and lid and conjunctivalcultures were obtained. Subjects were randomized to receive their firstdose of study medication at the study site, and received instructionsfor dosing at home and completing a diary.

The clinical signs were lid margin redness, lid swelling, bulbarconjunctival redness, palpebral conjunctival redness, and oculardischarge. The clinical symptoms were lid irritation, itchy eyelids,gritty eyes, and painful/sore eyes. The clinical resolution of clinicalsigns and symptoms were the primary efficacy variable. Bacterialeradication of baseline bacterial counts were the secondary efficacyvariable.

Primary Efficacy Endpoint: Clinical Resolution

The primary endpoint of the study is clinical resolution, defined as theabsence of all study clinical signs and symptoms. The ITT populationwith last observation carried forward (LOCF) data was used in theseanalyses for Visit 5 clinical resolution.

TABLE 2 Az + Dex Dex p-value 27.1% 23.5% 0.5807

As shown in Table 2, above, there was no significant difference betweenthe group treated with the combination of 1% azithromycin anddexamethasone and the group receiving dexamethasone alone. Dex was aseffective as the Dex+Az combination in treating blepharitis.

Secondary Efficacy Endpoint: Bacterial Eradication

The secondary efficacy endpoint is bacterial eradication of baselinebacterial species at Visit 5. Eradication was assessed for theconjunctiva and lid separately as well as combined. The mITT populationwith LOCF data was used in these analyses for Visit 5 clinicalresolution.

Combined (Eye Lid and Conjunctiva)

TABLE 3 Az + Dex Dex p-value 60.0% 40.2% 0.0068

As shown in Table 3, above, there was some improvement in the grouptreated with the combination of 1% azithromycin and dexamethasonerelative to the group receiving dexamethasone alone. However, themoderate antibacterial effect of dexamethasone alone in theophthalmically acceptable carrier of Table 1 provides an improvement inbacterial eradication more than double of that reported by Schulman etal. (supra).

Eye Lid Only

TABLE 4 Az + Dex Dex p-value 63.8% 40.9% 0.0029

As shown in Table 6, above, there was, again, some improvement in thegroup treated with the combination of 1% azithromycin and dexamethasonerelative to the group receiving dexamethasone alone. However, as above,the moderate antibacterial effect of dexamethasone alone in theophthalmically acceptable carrier of Table 1 provides an improvement inbacterial eradication more than double of that reported by Schulman etal. (supra).

Conjunctiva Only

TABLE 5 Az + Dex Dex p-value 79.6% 64.3% 0.1569

As shown in Table 5, above, there was, again, some improvement in thegroup treated with the combination of 1% azithromycin and dexamethasonerelative to the group receiving dexamethasone alone. However, as above,the antibacterial effect of dexamethasone alone in the ophthalmicallyacceptable carrier of Table 1 provides an improvement in bacterialeradication more than triple of that reported by Schulman et al.(supra).

EXAMPLE II Dexamethasone to Treat Blepharitis

This Example shows a composition with 0.1% Dexamethasone that is usefulin a method for treating blepharitis.

Table 6 below provides an exemplary formulation of the glucocorticoiddexamethasone as a 0.1% in an exemplary ophthalmically acceptablevehicle of the invention that included chitosan hydrochloride (U.S. Pat.No. 8,501,800).

TABLE 6 Concentration Amount Ingredient (% w/w) Per g (mg)Dexamethasone, 0.100 1.00 Micronized Mannitol, 1.100 11.00 Citric AcidAnhydrous, 0.200 2.00 Sodium Citrate 0.140 1.40 Dihydrate Poloxamer 4070.200 2.00 Benzalkonium 0.003 0.03 Chloride Polycarbophil 0.8125 8.125Chitosan Hydrochloride 0.025 0.25 Sodium Chloride 0.450 4.50 EdetateDisodium 0.100 1.00 Dihydrate Sodium Hydroxide Adjust to pH 6.3 Adjustto pH 6.3 Water for Injection qs to 100% qs to 1 g

In this example, a clinical study was to evaluate the clinical safety ofdexamethasone and polymer vehicle (DURASITE II, Table 6) as compared tothe polymer vehicle alone in the treatment of subjects with blepharitis.

In this Example, 550 subjects presenting with blepharitis were enrolled,366 treated with dexamethasone and polymer vehicle and 184 treated onlywith the polymer vehicle. The two groups of subjects presenting withblepharitis were treated twice daily (BID) for 14 days.

For clinical diagnosis of blepharitis, subjects had a minimum score of‘1’ for:

-   -   eyelid redness    -   eyelid swelling    -   eyelid debris    -   eyelid irritation

Subjects presenting with blepharitis were randomly assigned to the twogroups with a 2:1 ratio: Dexamethasone and polymer vehicle or polymervehicle alone. Subjects were dosed with Dexamethasone and polymervehicle or polymer vehicle alone BID at approximately 12-hour intervalsfor 14 days in both eyes. Subjects were instructed to place one drop ontheir eyelids. This was a multi-center, randomized, double-masked,3-arm, parallel-group, comparative clinical trial, with one interimanalysis.

After subjects met all entry criteria and signed informed consent, theyunderwent evaluations for visual acuity, biomicroscopy, ophthalmoscopy,and IOP. Signs and symptoms were evaluated. Subjects were randomized toreceive their first dose of study medication at the study site, andreceived instructions for dosing at home and completing a diary.

The clinical signs were eyelid margin redness, eyelid swelling, eyeliddebris, and eyelid irritation. The clinical symptoms were lidirritation, itchy eyelids, gritty eyes, and painful/sore eyes. Theclinical resolution of clinical signs and symptoms were the primaryefficacy variable.

Primary Efficacy Endpoint: Clinical Resolution

The primary endpoint of the study is clinical resolution, defined as theabsence of all study clinical signs and symptoms.

The effect of dexamethasone and the ophthalmically acceptable carrier ofTable 1 as compared to the ophthalmically acceptable carrier aloneprovides a significant improvement in subjects presenting withnon-infectious, inflammatory blepharitis.

Throughout this application various publications have been referencedwithin parentheses. The disclosures of these publications in theirentireties are hereby incorporated by reference in this application inorder to more fully describe the state of the art to which thisinvention pertains.

Although the invention has been described with reference to thedisclosed embodiments, those skilled in the art will readily appreciatethat the specific examples and studies detailed above are onlyillustrative of the invention. It should be understood that variousmodifications can be made without departing from the spirit of theinvention. Accordingly, the invention is limited only by the followingclaims.

What is claimed is:
 1. A method for treating non-infectious,inflammatory blepharitis in a subject, comprising: identifying a subjectsuffering from non-infectious, inflammatory blepharitis, and topicallyadministering to the eye of the subject a pharmaceutical formulationconsisting essentially of an effective amount of an a glucocorticoid inan ophthalmically acceptable vehicle for a sufficient period of time totreat blepharitis, said ophthalmi call y acceptable vehicle comprisingan aqueous polymer suspension that when mixed with tear fluid provides asustained release of said active ingredient, Wherein said aqueouspolymer suspension comprises a carboxyl-containing-polymer having lessthan about 5% by weight cross-linking agent and has a viscosity in arange from about 1,000 to about 30,000 centipoises.
 2. The method ofclaim 1, wherein the glucocorticoid is selected from the groupconsisting of hydrocortisone, cortisone acetate, prednisone,prednisolone, methylprednisolone, dexamethasone, betamethasone,triamcinolone, and beclometasone, fluorometholone.
 3. The method ofclaim 2, wherein the glucocorticoid is dexamethasone.
 4. The method ofclaim 1, wherein the glucocorticoid is present in a range from about0.05% and to about 0.5% by weight.
 5. The method of claim 4, wherein theglucocorticoid is present in a range from about 0.08% to about 0.12% byweight.
 6. The method of claim 3, wherein the glucocorticoid is presentin at about 0.1% by weight.
 7. The method of claim 1, wherein saidophthalmically acceptable vehicle further comprises a preservative. 8.The method of claim 1, wherein said preservative comprises benzalkoniumchloride.
 9. The method of claim 8, wherein said preservative is presentin a range from about 0.001 to about 0.005% by weight.
 10. The method ofclaim 1, wherein the average particle size of thecarboxyl-containing-polymer particles is in the range of 6 μm to 50 μm.11. The method of claim 1, wherein the carboxyl-containing-polymer ispresent from about
 0. 1% to about 6.5% by weight, based on the totalweight of the suspension.
 12. The method of claim 1, wherein thepharmaceutical formulation further comprises a second polymer as aviscosifier.
 13. The method of claim 12, wherein the second polymer ischitosan or a chitosan salt in an amount from about 0.01% to 0.5% byweight.
 14. The method of claim 13, wherein chitosan or chitosan salthas a molecular weight in a range from between about 50 kDa to about 100kDa.
 15. The method of claim 13, wherein chitosan or chitosan salt has amolecular weight in a range from between about 1000 kDa to about 3000kDa.
 16. The method according to claim 1, where the origin ofblepharitis is not related to bacteria.
 17. A kit comprising: (a) acomposition comprising about 0.1% by weight dexamethasone in anophthalmically acceptable vehicle, said ophthalmically acceptablevehicle comprising an aqueous polymer suspension that when mixed withtear fluid provides a sustained release of said active ingredient,wherein said aqueous polymer suspension comprises a carboxyl-containingpolymer having less than about 5% by weight cross-linking agent and hasa viscosity in a range from about 1,000 to about 30,000 centipoises, and(b) instructions for using the composition of (a) for the treatment ofnon-infectious, inflammatory blepharitis.